Health Care & Hospital Law
Mar. 13, 2024
Judge certifies class alleging maker of Parkinson’s drug misled investors
The lawsuit alleges that the company failed to disclose adverse information relating to its flagship Parkinson’s treatment drug, artificially inflating stock prices and causing substantial losses when it was revealed that the FDA would not approve the company’s application for expanded use.
A federal judge certified a class of investors who say a San Diego biopharmaceutical company failed to disclose adverse results in studies of its flagship Parkinson’s disease treatment drug, and misled the public into believing it would receive Food and Drug Administration approval for expanded use.
Acadia Pharmaceuticals Inc. develops and sells small-molecule drugs for the treatment of central nervous system disorders. The company develo...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In